Refractory celiac disease

Abdul R. Rishi, Alberto Rubio-Tapia, Joseph A. Murray

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Refractory celiac disease (RCD) affects patients who have failed to heal after 6-12 months of a strict gluten-free diet (GFD) and when other causes of symptoms (including malignancy) have been ruled out. It may also occur in patients who previously had responded to a long-term GFD. RCD may be categorized as RCD1 (normal immunophenotype) and RCD2 (aberrant immunophenotype). RCD1 usually responds to a continued GFD, nutritional support, and therapeutic agents such as corticosteroids. In contrast, clinical response in RCD2 is incomplete and prognosis is often poor. RCD (particularly RCD2) is associated with serious complications, such as ulcerative jejunitis and enteropathy-associated T-cell lymphoma (EATL). Strict clinical and laboratory criteria should be used to diagnose RCD and specialized tests for aberrancy and clonality should be interpreted in the context of their sensitivity and specificity. Adequate nutritional support and anti-inflammatory treatment may even allow patients with RCD2 to attain a clinical remission.

Original languageEnglish (US)
Pages (from-to)537-546
Number of pages10
JournalExpert Review of Gastroenterology and Hepatology
Issue number4
StatePublished - Apr 2 2016


  • Celiac disease
  • Gluten
  • Immune disorder
  • Refractory celiac disease
  • Small intestine

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Refractory celiac disease'. Together they form a unique fingerprint.

Cite this